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KESAN EKSTRAK AKAR EURYCOMA LONGIFOLIA JACK KEATAS
EREKSI ZAKAR ARNAB DAN ASAS MEKANISME TINDAKANNYA
ABSTRAK
Objektif kajian ini adalah untuk menilai kesan ekstrak hidro-alkohol akar
Eurycoma longifolia Jack kepada ereksi zakar dan asas mekanisme tindakannya.
Pengekstrakan akar E. longifolia Jack menggunakan metanol, etanol, dan air sebagai
pelarut menghasilkan tiga ekstrak iaitu; METEL, ETHEL dan AQUEL, masing-
masing. Kajian ketoksikan akut pada tikus jantan mendapati bahawa LD50 ≥ 2000
mg/kg bagi kedua-dua METEL dan ETHEL dan ≥ 5000 mg/kg bagi
AQUEL. Pemberian oral perencat PDE5, sildenafil pada 1.5, 3, 15, dan 30 mg/kg pada
arnab menyebabkan ereksi zakar sebanyak 1.6 ± 0.4, 3.1 ± 0.3, 8.6 ± 1.1, dan 10.9 ±
3.0 mm, masing-masing. Daripada tiga ekstrak, hanya METEL 500 dan 1000 mg/kg
menyebabkan ereksi zakar masing-masing 4.9 ± 1.4 dan 2.9 ± 0.9 mm dimana dos
terakhir telah mencapai kesan toksik. Penderma nitrik oksida (NO), natrium
nitroprusida (0.2 mg/kg, i.v.), dengan ketara mempotensiasi (P<0.001) ereksi aruhan
sildenafil lebih tinggi dari METEL (50 mg / kg, i.v.; P<0.05). Pemberian METEL (200
mg/kg, p.o.) dan testosteron enantat (30 mg / kg, s.c.) selama enam minggu
meningkatkan dengan ketara paras testosteron pada kedua-dua tikus dan arnab normal
(P<0.001-0.01). Begitu juga, paras NO telah meningkat dengan ketara pada arnab
normal dan diabetik oleh kedua-dua rawatan (P <0.001-0.05). Di samping itu,
berkurangannya tindak balas arnab diabetik kepada sildenafil telah diterbalikkan
dengan ketara oleh kedua-dua rawatan testosteron enantat dan METEL selama enam
minggu. Kajian ekspresi protein menunjukkan bahawa kedua-dua ekspresi nNOS dan
protein PDE5 telah berkurangan pada arnab diabetik namun diterbalikkan oleh
xxv
pemberian selama enam bulan METEL dan testosteron. Analisis HPLC mendapati
bahawa METEL, ETHEL dan AQUEL mengandungi 20.04 μg/mL, 19.79 μg/mL dan
21.71 μg/mL urokomanon (EN) masing-masing. Oleh itu, ereksi itu tidak telah
mungkin disebabkan oleh EN, suatu kuasinoid walaupun kuasinoid telah dibuktikan
terlibat dalam spermatogensis dan pengeluaran testosteron. Kesimpulannya,
pemberian akut ekstrak E. longifolia sendirian memberikan aktiviti ereksi zakar yang
sangat kecil dan hanya pada dos yang menghampiri kesan toksik. Walau
bagaimanapun, sama seperti testosteron, selepas pemberian kronik ia boleh digunakan
untuk meningkatkan ereksi mati pucuk separa seperti yang berlaku pada pesakit
diabetik.
xxvi
EFFECT OF ROOT EXTRACTS OF EURYCOMA LONGIFOLIA JACK ON
RABBIT PENILE ERECTION AND THE UNDERLYING MECHANISM OF
ACTION
ABSTRACT
The objective of this study was to assess the effect of hydro-alcoholic root
extracts of Eurycoma longifolia Jack on penile erection and its underlying
mechanisms. Extraction of roots of E. longifolia Jack using methanol, ethanol, and
water as solvent produced three extracts namely; METEL, ETHEL, and AQUEL,
respectively. Acute oral toxicity in male rats found LD50 of ≥ 2000 mg/kg for both
METEL and ETHEL and ≥ 5000 mg/kg for AQUEL. Oral administration of a PDE5
inhibitor, sildenafil at 1.5, 3, 15, and 30 mg/kg in rabbit caused penile erections of 1.6
± 0.4, 3.1 ± 0.3, 8.6 ± 1.1, and 10.9 ± 3.0 mm, respectively. Out of the three extracts,
only METEL 500 and 1000 mg/kg caused penile erections of 4.9 ± 1.4 and 2.9 ± 0.9
mm respectively, with the latter reached toxicity level already. Nitric oxide (NO)
donor, sodium nitroprusside (0.2 mg/kg, i.v.) significantly potentiated (p < 0.001)
sildenafil-induced erection higher than METEL (50 mg/kg, i.v.; p < 0.05). Six week
daily administration of METEL (200 mg/kg, p.o.) and testosterone enanthate (30
mg/kg, s.c.) significantly increased the testosterone level in both normal rats and
rabbits (p < 0.001 – 0.01). Similarly, NO level was significantly elevated in normal
and diabetic rabbits with both treatments (p < 0.001 – 0.05). In addition, diminished
responsiveness to sildenafil in diabetic rabbits was significantly reversed by both
testosterone enanthate and METEL after six weeks treatments. Protein expression
studies showed that both nNOS as well as PDE5 proteins were reduced in diabetic
rabbits which was reversed by both METEL and testosterone administration. HPLC
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analysis found that METEL, ETHEL, and AQUEL contain 20.04 µg/mL, 19.79
µg/mL, and 21.71 µg/mL, of eurocomanone (EN), respectively. Therefore, the erection
could not have been induced by EN – a potent quassinoid, although quassinoids have
been implicated in the spermatogensis and testosterone production. In conclusion,
acute administration of E. longifolia extract on its own has very little penile erection
activity and only at near toxic doses. However, similar to testosterone, after chronic
use it may improve partial erectile dysfunction such as in diabetic patient.
11 CHAPTER 1: GENERAL INTRODUCTION
1.1 Introduction
Penile erection is an important physiological phenomenon which is vital for a
successful penetration during intercourse. A normal erection in a male adult usually
involves a set of complex neurovascular events that give rise to increased supply of
arterial blood into sinusoidal spaces in the penis in response to supraspinal responses
(Andersson, 2011). Several distinct neurotransmitters as well as mediators regulate
penile erection. A solid erection is necessary for a successful penetration of vaginal
cavity during sexual contact.
Normal penile erection is usually affected by several risk factors such as aging,
smoking, cardiovascular diseases, neurological diseases/disorders, endocrine defects,
certain medications, hormonal abnormalities, and radical prostatectomy. These,
individually or collectively, lead to endothelial dysfunction in general which results in
the failure of smooth muscle relaxation during erection. Endothelial insufficiency then
gives rise to erectile dysfunction (ED) in men (de Mendonça, 2012).
The fact that ED is not a life-threatening condition makes it difficult to estimate
its incidence as many men with ED do not seek treatment (Melman, 1999). Findings
of a study conducted in 1290 men of 40-70 years old between 1987 and 1989 indicated
an overall prevalence of ED of 52% (Feldman, 1994). Elsewhere, a relatively recent
report suggested a prevalence rate of ED of 18.4% in men aged 20 years and above
which were mainly age-related (Selvin, 2007).
2Since its discovery as a substance capable of inducing penile erection in male,
Sildenafil – a potent inhibitor of phosphodiesterase-5 (PDE5) enzyme, has played
important role in treating ED in men by enhancing the erectile capacity of the penis.
Few other PDE5 inhibitors such as vardenafil, tadalafil, and mirodenafil have also been
introduced to improve penile erection in men with ED. Despite this, satisfactory
erections are not produced in men with severe diabetes or cardiovascular diseases by
these agents. However, side effects associated with long-term use of these agents have
limited their use in the treatment of ED (Raina, 2003, McMurray, 2007).
Generally, androgens play vital role in the growth and development of sexual
organs as well as in regulating various metabolic functions in the body. Also, erectile
function is largely influenced by sexual hormones predominantly by androgens and
the deficiency of which may lead to impotence in men (Smith, 2001). Adequate
production of androgens mainly testosterone is essential in the preservation of healthy
and functional erectile function in men in order to enhance libido and sexual
performance. Besides, they indirectly regulate the expression of several proteins viz.
neuronal nitric oxide synthase (nNOS), endothelial nitric oxide synthase (eNOS), and
PDE5 which are key mediators involved in the stimulation and maintenance of penile
erection (Traish, 2005, Zhang, 2005). Androgen deprivation results in
hypoandrogenism (male hypogonadism) which may arise as a complication of genetic
and/or autoimmune abnormalities, systemic diseases, tumor, radiation, injury, aging,
infection, and medical or surgical castration in men (Seftel, 2006, Sterling, 2015).
Testosterone replacement therapy or gonadotropin releasing hormones
(GnRHs) have been prescribed to correct low testosterone levels and hypogonadism
which occurs mainly in middle-aged and old men or those with ED (Sterling, 2015).
3Also, some investigations have suggested the concomitant use of testosterone and
PDE5 inhibitors which have been proven to be effective in managing erectile
dysfunction (Alhathal, 2012). However, this is associated with higher risk of
hematocrit and prostate cancer in middle-aged & old men (Calof, 2005, Marks, 2006
).
For ages, men have used herbs with potentials to treat sexual dysfunction
(impotence). Traditional remedies prepared from various herbs like Tribulus terrestris,
Myristica fragrans, Psoralea coryifolia, Eurycoma longifolia, Satureja khuzestanica,
Fadogia agrestis, Panax ginseng, Avena sativa, Butea frondosa, Withania somnifera
(Ashwagandha), Lepidium meyenii, Phoenix dactylifera, Montanoa tomentosa, Chione
venosa, Ruta chalepensis, Eriosema kraussianum, and Gingko biloba have shown
promising outcomes in managing infertility and sexual impairments in various animal
models (Malviya, 2011).
Similarly, there are numerous reports recognizing aphrodisiac potentials of E.
longifolia root extracts in human as well as rodents. So far, much of the
pharmacological investigations pertaining to aphrodisiac effect of E. longifolia have
mainly focused on the assessment of spermatogenesis and steroidogenesis in normal
and/or castrated animal models. Besides, there are several other studies which have
evaluated penile reflexes, sexual motivation, mating behaviour, mount frequency,
orientation activity, ejaculation frequency, intromission frequency, sexual
performance, sexual quality, post-ejaculatory interval, pro-androgenic effect, and
copulatory behaviour in rodents mainly rats (Wizneh, 2014). Despite this, there has
been no investigation which would evaluate the effect of E. longifolia root extract on
penile erection and its underlying mechanism of action in both normal and disease-
4induced ED models. Moreover, influence of E. longifolia on mediators of penile
erection such as nNOS, eNOS, and PDE5 which are indirectly regulated by
testosterone have not been studied so far.
Based on the above discussions, this study was undertaken to explore the
impact of short- and long-term administration of hydro-alcoholic root extracts of E.
longifolia on penile erection and the possible underlying mechanism of action in both
normal and diabetes-induced ED in animal models. Additionally, characterization of
the bioactive extract/s by high performance liquid chromatography were executed to
standardize these through detection and quantification of the most active constituent.
51.2 Research Objectives
1) To perform hydro-alcoholic extraction of roots of Eurycoma longifolia Jack.
2) To carry out acute oral toxicity of hydro-alcoholic extracts of Eurycoma longifolia
Jack in adult male Sprague Dawley rats.
3) To study the effect of acute administration of root extracts of Eurycoma longifolia
on penile erection in conscious adult male New Zealand white rabbits.
4) To investigate the effect of root extracts of Eurycoma longifolia on serum
testosterone level in normal and streptozotocin-induced diabetic male SD rats.
5) To study the effect of chronic administration of bioactive extracts of Eurycoma
longifolia on penile erection in normal and alloxan-induced diabetic adult male
New Zealand white rabbits.
6) To estimate the testosterone and nitric oxide levels in the serum samples of normal
and diabetic rabbits following chronic administration of methanol extract
(METEL) of Eurycoma longifolia.
7) To study the effect of chronic administration of methanol extract (METEL) of
Eurycoma longifolia on the expression of PDE5, nNOS, and eNOS proteins in
penile protein samples of normal and diabetic rabbits through SDS-PAGE and
western blot analysis.
8) To detect and quantitate eurycomanone (EN) in the bioactive extracts of Eurycoma
longifolia by means of reversed-phase high performance liquid chromatography
technique.
62 CHAPTER 2: LITERATURE REVIEW
2.1 Penile Erection
In a normal healthy adult an erection involves a set of complex neurovascular
process which arises in response to several supraspinal stimuli (Andersson, 2011). A
normal penile erection consists of some individually distinct components as sexual
desire (libido), penile tumescence (erection), the climax of sexual excitement
(orgasm), seminal discharge (ejaculation), and penile detumescence (refractory
period) (Milhoua, 2006). The term “erection” itself is defined as “the state marked by
firm turgid form and erect position of a previously flaccid bodily part containing
cavernous tissue when that tissue becomes dilated with blood” (Merriam-Webster,
2014b). In other words, penile erection is the state of engorgement of smooth muscles
of corpora cavernosa (CC) due to augmented blood flow via dilated blood vessels in
the penis. It is the ultimate consequence of a spinal response to central and autonomic
neural and/or humoral processes. Penile erection ensues when the influx of blood to
the corpora cavernosa outweighs its outflow and therefore causes the sinusoidal
enlargement. Meanwhile, the emissary mechanism is repressed to prevent drainage of
blood out of penis (Lue, 2000). A firm erection is desirable to penetrate the vaginal
cavity during sexual intercourse.
The building blocks of male reproductive system comprises internal and
external genital structures which include spermatic cord, scrotum, testes, epididymis,
vas deferens, prostate gland, paradidymis, ejaculatory ducts, seminal vesicles,
7bulbourethral glands, and penis (Standring, 2008). These play essential role in
facilitating a normal erectile function in men through multifaceted neurovascular
mechanisms.
2.1.1(a) Penis
Penis is the male sexual organ for intercourse that is present in a continuum
from flaccid to fully rigid state (Milhoua, 2006). Structurally it looks like a cylindrical
tissue anchored to the inferior pubic rami. Essentially, it consists of an attached root
(radix) in the perineum and a free hanging body known as corpus. It is a muscular body
that plays major role in delivering semen into the vagina during sexual intercourse and
also in urinal discharge (Standring, 2008).
2.1.1(a)(i) Skin
The penis skin is a thin layer which wraps the entire penile tissue. Over the
corona of penis, it forms a layer covering the penis glans which is known as prepuce.
Proximal to the penis orifice, it forms the frenulum right below the neck of the penis.
2.1.1(a)(ii) Root
Two crura of the penis and bulb form the root of the penis. The crura – rounded
elongated structures enclosed by ischiocavernosus and strongly attached to the
ischiopubic rami, are connected to the pubic arch while the bulb is attached to the
perineal membrane (Standring, 2008).
82.1.1(a)(iii) Body
Two erectile tissue masses namely corpora cavernosa and the median corpus
spongiosum which are the continuation of the crura and bulb of the penis respectively,
shape the main body of the penis. See Figure 2.1. These tissues are filled with blood
during penile erection. A flaccid penis is cylindrical in shape but changes to triangular
form when erect (Standring, 2008).
9Figure 2.1 Anatomical illustration of human penis body.
2.1.1(a)(iv) Corpora Cavernosa
There are two corpus cavernous tissues running parallel to each other on the
dorsal surface of the penis above corpus spongiosum which are analogous cylindrical
erectile tissues enveloped in tunica albuginea. These are separated by a wide median
septum on urethral surface and a narrower one at the dorsal surface. They originate
from the crura of the penis CC, run along the length of the penis, and end distally
within the proximal part of the glans penis. Sinusoidal spaces within CC are dilated
with blood during the course of erection by cavernous arteries which run the length of
the CC (Standring, 2008). See Figure 2.2.
Figure 2.2 Cross section of the body of penis (Standring, 2008).
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2.1.1(a)(v) Corpus Spongiosum
A spongy-like cylindrical tissue through which urethra passes and is
surrounded by tunica albuginea. It borders the central groove on the urethral surface
of the conjoined CC and ends at glans penis. The urethra within corpus spongiosum
ends at the external urethral orifice (meatus) of glans penis which facilitates urinal and
seminal discharge. Blood supply via bulbourethral and to some extent dorsal arteries
during an erection results in the elongation of its sponge-like structure (Milhoua, 2006)
2.1.1(a)(vi) Penile Fascia
Penile fascia are of two types; superficial and deep fascia. Superficial penile
fascia, also known as “Dartos fascia” is made of loose connective tissue without fat
underneath which superficial dorsal vein of the penis extends along the penile shaft.
The deep penile fascia also known as Buck’s fascia is rather compressed to shape a
discrete strong sheath which covers both CC and corpus spongiosum. In addition, it
accommodates deep dorsal vein, dorsal arteries, and dorsal nerves (Standring, 2008).
2.1.1(a)(vii) Suspensory Ligaments of Penis
Composed mostly of elastin fibers, suspensory ligaments provide support to
penis body during erection and flaccid state. Fundiform suspensory ligament springs
from the lowest part of the linea alba and splits into two fasciculi which encircles the
body of the penis. The triangular suspensory ligament however is situated deeper to
the fundiform ligaments which extends from the pubic symphysis and unites at the
base of the penis before septum of the scrotum (Standring, 2008).
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2.1.1(a)(viii) Penile Vasculature
Arterial supply of the penis
Arterial blood supply of penis is mainly attributed to the internal pudendal
artery which ascends from internal iliac artery. It further branches off into dorsal,
cavernosal and bulbourethral arteries which deliver arterial blood into various tissues
of the penis. Dorsal or superficial penile arteries which are the terminal branch of the
internal pudendal artery end at glans penis and prepuce by travelling between crus
penis and pubic symphysis, and then by penetrating through suspensory ligaments of
the penis. These lie deep to Buck’s fascia and give rise to circumflex arteries that run
laterally along the shaft of the penis and which predominantly supply tunica albuginea
and to some extent corpus spongiosum. Cavernous artery also known as deep artery of
the penis is the other terminal branch of the internal pudendal artery. It penetrates
tunica albuginea, enters the crus penis at the penile hilum, and runs medially along the
length of the corpus cavernosum. Cavernous arteries within CC give rise to two types
of arteries; outer capillaries and inner helicine arteries. The outer capillaries play
important role in penile nutrition during the flaccid state and supplying the smooth
muscle and nerve fibers whereas the latter help in penile elongation and erection
without compromising blood flow. Bulbourethral artery which is a short artery of large
caliber also originates from internal pudendal artery. See Figure 2.3. It supplies both
bulbourethral gland of the penis and corpus spongiosum (Benoit, 1987, Banya, 1989,
Breza, 1989, Montorsi, 1998, Standring, 2008).
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Figure 2.3 Arterial supply of the penis (Standring, 2008).
Venous supply of penis
Three sets of veins; superficial, intermediate, and deep facilitate venous
emptying of penile tissues. See Appendix 2.1. The superficial dorsal veins mainly draw
off blood from the skin and subcutaneous tissues superficial to Buck’s fascia which
subsequently drains into external pudendal vein. The intermediate set of veins which
empty the glans penis are located deep to Buck’s fascia. These form a retrococcal
plexus that drain into deep dorsal vein which ultimately drains into Santorini’s plexus
(periprostatic plexus). Both the CC and corpus spongiosum are drained via deep
venous system. Emissary veins of the middle and distal penis formed through
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coalescence of postcavernous venules unite to shape circumflex veins which empty
into deep dorsal vein. The emissary veins of the proximal penis however give rise to
cavernous vein which drains into internal pudendal vein (Fournier, 1987, Aboseif,
1989, Fuchs, 1989, Lue, 1996, Moscovici, 1999).
Lymphatic drainage
Penile lymph vessels that accompany the external pudendal blood vessels to
the superficial inguinal nodes are responsible for the drainage of penile skin. Lymph
vessels that drain the glans penis enter the external iliac nodes whereas the lymph
vessels of urethral and erectile tissues drain into internal iliac nodes (Standring, 2008).
2.1.1(a)(ix) Penile innervation
Neural regulation of erectile function in male is mediated by the autonomic
nervous system (ANS) through sympathetic and parasympathetic input. The penis is
innervated with nerve fibers stemming from T11 – L2 segments of thoracolumbar
(sympathetic) and S2 – S4 segments of sacral (parasympathetic) spinal cord. See
Figure 2.4. Stimuli originating from parasympathetic source trigger penile erection
whereas sympathetic outflow prompts penile contraction and flaccidity. Neural
stimulus instigates the release of key neurotransmitters; Acetylcholine (ACh;
parasympathetic), noradrenaline (NA; sympathetic), and nitric oxide (NO; non-
adrenergic non-cholinergic (NANC)) which play distinct role during erectile function
(Taub, 1993). The penis is innervated with three types of nerve fibers: dorsal, perineal,
and cavernousal. Dorsal and perineal nerves both ascend from pudendal nerves. The
dorsal fibers supply sensation to penile skin by traveling within Buck’s fascia along
with dorsal arteries and veins while the perineal nerves innervate bulbospongiosus
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muscle, ventral shaft skin, and the frenulum (Brooks, 2007). On the other hand,
cavernous nerves arising from autonomic pelvic plexus travel along the periprostatic
neurovascular bundle and penetrate the cavernous tissue underneath the pubic arch
(Akman, 2001, Yucel, 2003). Cavernous nerve which contains both parasympathetic
and sympathetic components divides into two nerve fibers: lesser cavernous nerve and
greater cavernous nerve. The former innervates the urethral and spongiosus erectile
tissues whereas the latter enters CC about the vessels in the hilum of the penis (Lepor,
1985, Lue, 1984).
2.1.1(b) Scrotum
The scrotum is a cutaneous fibromuscular sac hanging below the pubic
symphysis between the thighs which is house to testicles, epididymis, paradidymis,
vas deferens, and Spermatic cord. It comprises of skin, superficial (Dartos) fascia,
external spermatic fascia, cremaster muscle and fascia, internal spermatic fascia, and
parietal layer of tunica vaginalis. A cutaneous raphe divides the scrotum into two
halves; left and right. Presence of a longer spermatic cord on the left side of the scrotum
makes it seem slightly lower than the right side.
2.1.1(b)(i) Testes
Testes are the primary reproductive gonads of the male which are ovoid in
shape and are responsible for both spermatogenesis and androgen production mainly
testosterone. They are components of both reproductive and endocrine system. The
average weight of testes differs among individuals which is from 10.5 – 14 g; the
average dimensions are; 4 – 5 cm in length, 2.5 cm in breadth, and 3 cm in
anterioposterior diameter. Within the scrotum the testes are suspended by Dartos
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muscle and spermatic cords. The right testis is usually positioned slightly higher than
left testis within the scrotum. Each testis is supplied by three coats which are, from
inside outwards, the tunica vasculosa, tunica albuginea, and tunica vaginalis
(Standring, 2008).
2.1.1(b)(ii) Epididymis
The epididymis is invested by tunica vaginalis and is responsible for the storage
of the sperms and its transportation from the testes. It is positioned posterio-lateral to
the testis and consists of three parts: globus major (head), corpus (body), and
cauda/globus minor (tail). A deep depression known as the sinus epididymis is present
laterally between the testis and the epididymis (Standring, 2008).
2.1.1(b)(iii) Vas deferens
The vas deferens (ductus deferens) arises as a muscular conduit at the end of
the epididymis is of 45 cm long which carries sperm to the ejaculatory ducts. It is the
direct continuation of the canal of the epididymis. It is quite tortuous in the beginning
and straightens as it rises the posterior part of the testis (Standring, 2008).
2.1.1(b)(iv) Paradidymis
Paradidymis is a vestigial body which is found above the epididymal head and
anteriorly in the spermatic cord is a collection of circuitous tubules. Generally, it is
believed to be a remnant of the mesonephros which is covered by the ciliated columnar
epithelial tissue (Standring, 2008).
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Figure 2.4 Schematic representation of the penile innervation.
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2.1.1(b)(v) Spermatic Cord
As the name indicated the spermatic cord is a cord-like structure which consists
of (a) vas deferens, (b) the testicular artery and pampiniform plexus of veins, (c) the
lymph vessels and nerves of the penis and epididymis, and (d) remains of the processus
vaginalis. It stretches from the testis all the way to the deep inguinal ring. Three sheaths
of tubular in nature viz. the external spermatic fascia, the cremasteric muscle and
fascia, and internal spermatic fascia enclose the spermatic cord (Standring, 2008).
2.1.1(c) Ejaculatory ducts
The merging of the duct of seminal vesicle with the ampulla of the ductus
deferens establish the ejaculatory duct on either side. Length of each ejaculatory duct
is less than an inch (about 2 cm) which begins at the bottom of the prostate and travels
anterioinferiorly between its median and left/right lobes. The ducts pass through the
prostate and open into the urethra at the colliculus seminalis/verumontanum by slit-
like apertures. They facilitate the ejaculation of semen which passes through prostate
into urethra during ejaculation process (Martin, 1951, Standring, 2008).
2.1.1(d) Seminal vesicles
Seminal vesicles (seminal glands/vesicular glands) are a pair of hollow
sacculated organs which lie inferiorly to the bladder and in front of the rectum. Each
vesicle is about 3 – 4 mm in diameter which look slightly pyramidal in shape.
Basically, a seminal vesicle is a single twisted duct with non-uniform diverticula. A
coiled tube measures approximately 2 inches in length whereas its unravelled length
is ranges from 10 – 15 cm (Martin, 1951). A substantial percentage of the seminal fluid
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(70 – 85%) is secreted by seminal vesicular glands which is alkaline in nature
(Kierszenbaum, 2011).
2.1.1(e) Bulbourethral glands
The bulbourethral glands (glandulae bulbourethrales) are two tiny, spherical,
and to some extent lobulated masses of a yellow color. Each gland measures about 1
cm (roughly the size of a pea) in diameter which is surrounded by transverse fibers of
the sphincter urethrae. These are exocrine glands which sit lateral to the membranous
part of the urethra between the sheets of the fascia of the urogenital diaphragm.
Bulbourethral glands produce a mucus-like fluid called as pre-ejaculate during sexual
arousal which makes the urethra more hospitable for the sperm to pass through by
neutralizing its acidic environment (Gray, 1972, Britannica, 2014).
2.1.1(f) Prostate gland
The prostate is a partly glandular, partly muscular reproductive organ of male
which if of dark red-brown color. It is a firm structure surrounded by a dense fascia
sheath which is placed within the pelvic cavity behind the pubic symphysis. Prostate
is about the size and shape of a chestnut. It has an apex that faces downwards, an
upward looking base, a posterior surface, a pair of lateral surfaces, and an anterior
surface. Prostate secretes a slightly alkaline fluid that is milky/white in appearance to
nourish the semen and to help enhance the lifespan of spermatozoa by augmenting its
motility in acidic environment of vaginal tract. Prostatic fluid along with fluid from
seminal vesicles and spermatozoa constitute approximately 30% of the semen volume
(Standring, 2008).
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Penile erection and contraction are neurovascular phenomenona involving
nerve fibers, blood vessels and tissue cavities, and smooth muscle cells of the target
organ. Penile erection is a process that is mainly mediated through spinal response
which comprises of various central and peripheral mechanisms. Olfactory,
imaginative, visual, and tactile stimuli which originate from central nervous system
(CNS) as well as peripheral nervous system (PNS) can trigger release of certain
neurotransmitters that promote smooth muscle relaxation. These facilitate increase
inflow of oxygenated blood into corporeal smooth muscle which results in the
sinusoids to be stretched and expanded to accommodate more blood to produce
erection. Relaxation and elongation of corporeal smooth muscles compress the
surrounding internal venules to hinder blood outflow. Therefore, allowing the
intracavernosal pressure to rise to mean systolic pressure to cause penile rigidity
(Rehman, 2001, Andersson, 2011).
Relaxation of smooth muscle cell is mainly brought about by the action of
neurotransmitter NO. Following the excitatory signals from the supraspinal region
parasympathetic cholinergic nerve endings within corpus cavernosum (CC) release
ACh which promotes the formation and release of NO mediated by endothelial nitric
oxide synthase (eNOS) from endothelial cells. Meanwhile, non-adrenergic non-
cholinergic (NANC) nerves in CC also release NO via the action of neuronal nitric
oxide synthase (nNOS). NO then diffuses into the smooth cell and activates the soluble
guanylyl cyclase (sGC) which facilitates the conversion of guanosine triphosphate
(GTP) into cyclic guanosine monophosphate (cGMP) which in turn activates cGMP-
specific protein kinase (PKG). In the meantime, prostaglandin E1 (PGE1) activates
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enzyme adenylyl cyclase (AC) by binding to G-protein-coupled-receptor (GPCR)
promoting the formation of cyclic adenosine monophosphate (cAMP) which in turn
activates cAMP-specific protein kinase (PKA). Activation of both PKG and PKA
causes reduction in intracellular Ca+2 levels by (1) inhibiting its influx, (2) stimulating
its uptake by endoplasmic reticulum (ER), and (3) activating the efflux of K+.
Subsequently, myosin head detaches from actin triggering the relaxation of smooth
muscle cells which leads to increased inflow of blood and ultimately penile erection
(Lue, 2000, Corona, 2010, Andersson, 2011).  See Figure 2.5.
On the other hand, penile detumescence (flaccidity) or contraction occurs
mainly as a consequence of stimulation by sympathetic nervous system in the penile
tissues. Release of anti-erectile neurotransmitters such as norepinephrine (NE) from
adrenergic nerve endings in penile tissues stimulate the release of calcium ions and
hence promotes contraction of the smooth muscle cells. Meanwhile, NE triggers the
activation of Rho-A/Rho-kinase pathway which results in calcium sensitization
leading to smooth muscle cell contraction and penile flaccidity (Andersson, 2011). NE
released from adrenergic nerve endings of sympathetic nervous system binds to α1
receptor in the smooth muscle cell membrane, stimulating both phospholipase C (PLC)
and guanine nucleotide exchange factors (GEFs). Stimulated GEFs facilitate the
activation of Rho-A signaling pathway by converting inactive Rho-A GDP into its
active form Rho-A GTP. This in turn activates Rho-associated protein kinase (ROCK)
protein which facilitates the phosphorylation of myosin light chain leading to the
contraction of smooth muscle cells. Meanwhile, activation of PLC generates inositol
triphosphate (IP3) which triggers the augmentation of intracellular Ca+2 concentration.
This is followed by formation of calcium – calmodulin complex which causes the
phosphorylation of myosin light chain by stimulating the action of myosin light chain
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kinase (MLCK) leading to the contraction of penile tissues (Lue, 2000, Corona, 2010).
See Figure 2.6.
Figure 2.5 Molecular mechanism of penile smooth muscle relaxation. ACh;
acetylcholine, PGE1; prostaglandin E1, AC; adenylyl cyclase, GPCR; G-protein
coupled receptor, cAMP; cyclic adenosine monophosphate, cGMP; cyclic guanosine
monophosphate, ER; endoplasmic reticulum, ATP; adenosine triphosphate, 5’AMP;
5’adenosine monophosphate, PKA; cAMP-specific protein kinase, PKG; cGMP-
specific protein kinase, sGC; soluble guanylyl cyclase, PDE; phosphodiesterase
enzyme, eNOS; endothelial nitric oxide, IP3; inositol triphosphate, NO; nitric oxide,
GTP; guanosine triphosphate, 5’GMP; 5’guanosine monophosphate.O2; oxygen, Ca+2;
calcium ions, K+; potassium ions. (Adopted from Lasker et al. 2006).
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Figure 2.6 Molecular mechanism of smooth muscle contraction of the penis. NE;
norepinephrine, CLCA; calcium-activated chloride channels, VOC; voltage
operated channel, PLC; phospholipase C, IP3; inositol triphosphate,  CAL;
calmodulin, GEFs; Guanine nucleotide exchange factors, GAPs; GTPase-activating
proteins, ROCK; Rho-associated protein kinase, Rho-A; ras-homolog gene family
member A, MLC; myosin light chain, MLCK; myosin light chain kinase, MLCP;
myosin light chain phosphatase, CPI-17; C-kinase-activated protein phosphatase-1
inhibitor-17. (Adopted from Corona et al. 2010).
2.1.2(a) Central Regulation of Penile Erection
Mechanism of central regulation of erectile function involves both spinal and
supraspinal pathways. Findings of earlier investigations suggest that the male sexual
arousal is largely regulated by the limbic system and hypothalamus under central
supraspinal systems. Also, some key structures viz. paraventricular nucleus (PVN),
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medial preoptic area (MPOA), medial amygdala, the periaqueductal gray, and ventral
tegmentum play major role in the central management of male sexual function.
Moreover, studies have recommended that the electrical stimulation of the MPOA and
PVN or even the hippocampal formation gives rise to penile erection (Giuliano, 2000a,
b, Andersson, 2011, Melis, 2011). Various neurotransmitters and neuropeptides;
excitatory or inhibitory, regulate penile erection among which 5-HT (5-
hydroxytryptamine/serotonin), oxytocin, dopamine (DA), nitric oxide (NO),
excitatory amino acids, adrenocorticotropin/α-melanocortin stimulating hormone (α-
MSH), and opioid peptides are well recognized. These either facilitate or inhibit penile
erection by acting in different regions of the brain with the PVN being major one
(Melis, 2011, Andersson, 2011).
2.1.2(a)(i) Proerectile Mediators
Certain central neurotransmitters such as dopamine, oxytocin, excitatory
amino acids, adrenocorticotropins/melanocortins, hezarelin analog peptides, pro-VGF
nerve growth factor inducible (VGF) derived peptides, cannabinoids, NO, prolactin,
androgens have demonstrated facilitative effects on male sexual functions in general
in number of animal models. Injection of several dopaminergic agonists have shown
to induce penile erection in mammals following systemic administration (Hull, 2004,
Melis, 1995). A similar proerectile effect was observed when oxytocin was injected
into the PVN or other extrahypothalamic regions of the brain which was suggested to
be due to the presence of a group of oxytocinergic neurons (Argiolas, 2004,
Baskerville, 2008, Melis, 2011). Besides, evidence from several anial studies revealed
that the injection of excitatory amino acids; NMDA (Argiolas, 2005, Melis, 1994),
hexarelin analog peptides (Melis, 2001, Argiolas, 2005), pro-VGF-derived peptides
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(Argiolas, 2005), nitric oxide (Argiolas, 1994), and
adrenocorticotropins/melanocortins (Bertolini, 1975, Wessells, 2005, King, 2007)
agonists and cannabinoids antagonist (Melis, 2004) into the PVN induced penile
erection via diverse mechanisms. Androgens, in particular testosterone have been
shown to have important role in regulating erectile function (both centrally and
peripherally) absence of which causes a decline in erectile and ejaculatory functions
in male (Traish, 2007, Buvat, 2010). Short-term central prolactin treatment is
associated with stimulatory effect on sexual behavior in rodents (Cruz-Casallas, 1999).
2.1.2(a)(ii) Anti-erectile Mediators
Reports suggest that anti-erectile central neurotransmitters like serotonin/5-
HT, γ-amino butyric acid (GABA), opioid peptides, and prolactin as well as NE to
certain extent suppress the sexual function in male. Serotonin being the most
distinguished of all is thought to have a general inhibitory effect on male sexual
activities which comprises both sympathetic and parasympathetic, and somatic
outflow pathways (Hull, 2004, Marson, 1992, Bitran, 1987). Generally,
hyperprolactinemia is linked with depressant effect on sexual behavior and reduction
in sexual potency as well as sexual reflexes in male. Moreover, long-term central
prolactin treatment is associated with inhibitory effect on the sexual behavior (Drago,
1984, Cruz-Casallas, 1999, Rehman, 2000, Kruger, 2005). Studies on the role of the
GABA in erectile function have underlined the general inhibitory action of this
neurotransmitter in the pathways involved in penile erection (de Groat, 1993, Melis,
2002). However, a study in male rats revealed that the activation of GABAA subtype
receptor reduces copulatory activity while its GABAB subtype receptor stimulation
